Genicell technology aims to expedite and lower the cost of drug development by reducing the time and money spent bringing drugs to market. It does this by providing a more effective way to test novel drug compounds during preclinical trials, which could filter out 98% of compounds that typically fail at this stage. This approach seeks to both shorten the drug development timeline from 10-12 years as well as lower the nearly $1 billion average cost per approved drug.
1. | Expediting and lowering the cost of the drug development process |
www.genicell.co
Angelist Profile
2. Summary
• Costs ~$1 Billion to bring
a single drug to market.
• 98% of novel compounds
fail preclinical test stage.
• Genicell technology
provides 3 major benefits:
– Reduces the amount of time
necessary to bring a drug to
market
– Lowers the cost of drug
discovery/testing
– Reduces the number of
animals used during drug
development
4. Pain
• Pharmaceutical companies are researching alternative
ways to evaluate novel compounds to compensate for the
increasing prices of typical go-to-market strategies.
• Typical time to market for new drug is 10-12 years and
costs close to $1 Billion
• We can funnel out the compounds that will fail the
preclinical testing stage before they enter these expensive
trials.
5. Genicell Technology
Intellectual Property Potential
• Novel bioreactor
(provision filed 3/2012)
• Cells used to create
construct
• Protocol for using
system and testing
drugs
6. Market and Customer Segments
1. Pharmaceutical Companies/Contract Research Organizations (CROs)
2. Small molecule companies
3. Researchers in Academia
7. Go-to-market Strategy
• Sell bioreactor technology to researchers and
CROs
• Market Genicell BBB testing to small
molecule companies as an addition to their
available testing suite
• Following side-by-side testing of data
gathered in our system vs. data collected
from animals, we would be able to fully insert
ourselves into the drug discovery pipeline for
pharmaceutical companies